JP2018519327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519327A5 JP2018519327A5 JP2017568200A JP2017568200A JP2018519327A5 JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5 JP 2017568200 A JP2017568200 A JP 2017568200A JP 2017568200 A JP2017568200 A JP 2017568200A JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- combination according
- administered
- immunotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021143803A JP2021183650A (ja) | 2015-06-29 | 2021-09-03 | 治療用組成物、組合せ物および使用の方法 |
| JP2024100476A JP2024111247A (ja) | 2015-06-29 | 2024-06-21 | 治療用組成物、組合せ物および使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186197P | 2015-06-29 | 2015-06-29 | |
| US62/186,197 | 2015-06-29 | ||
| PCT/US2016/040080 WO2017004192A1 (en) | 2015-06-29 | 2016-06-29 | Therapeutic compositions, combinations, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021143803A Division JP2021183650A (ja) | 2015-06-29 | 2021-09-03 | 治療用組成物、組合せ物および使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018519327A JP2018519327A (ja) | 2018-07-19 |
| JP2018519327A5 true JP2018519327A5 (https=) | 2019-07-11 |
Family
ID=57609144
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568200A Withdrawn JP2018519327A (ja) | 2015-06-29 | 2016-06-29 | 治療用組成物、組合せ物および使用の方法 |
| JP2021143803A Withdrawn JP2021183650A (ja) | 2015-06-29 | 2021-09-03 | 治療用組成物、組合せ物および使用の方法 |
| JP2024100476A Pending JP2024111247A (ja) | 2015-06-29 | 2024-06-21 | 治療用組成物、組合せ物および使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021143803A Withdrawn JP2021183650A (ja) | 2015-06-29 | 2021-09-03 | 治療用組成物、組合せ物および使用の方法 |
| JP2024100476A Pending JP2024111247A (ja) | 2015-06-29 | 2024-06-21 | 治療用組成物、組合せ物および使用の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10532056B2 (https=) |
| EP (2) | EP3313404B1 (https=) |
| JP (3) | JP2018519327A (https=) |
| KR (1) | KR102783581B1 (https=) |
| CN (2) | CN114209841A (https=) |
| AU (3) | AU2016286091B2 (https=) |
| CA (2) | CA3244408A1 (https=) |
| EA (1) | EA201890161A1 (https=) |
| ES (1) | ES2987376T3 (https=) |
| IL (2) | IL256652B2 (https=) |
| MX (2) | MX389683B (https=) |
| WO (1) | WO2017004192A1 (https=) |
| ZA (1) | ZA201800572B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| TR201907147T4 (tr) | 2013-07-18 | 2019-06-21 | Taiho Pharmaceutical Co Ltd | Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. |
| SG10201805890QA (en) * | 2014-01-09 | 2018-08-30 | Verastem Inc | Compositions and methods for treatment of abnormal cell growth |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| JP6823067B2 (ja) | 2015-09-10 | 2021-01-27 | タンボ・インコーポレイテッド | 生体直交型組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| UY37594A (es) | 2017-02-07 | 2018-08-31 | Univ Saitama Medical | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer |
| ES2983582T3 (es) | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| US11452764B2 (en) * | 2017-07-21 | 2022-09-27 | University Of North Dakota | Inhibiting FAK-AKT interaction to inhibit metastasis |
| JP2021517589A (ja) * | 2018-03-12 | 2021-07-26 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| CN110960679A (zh) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | 一种抗肿瘤的药物组合物及其应用 |
| WO2020135442A1 (zh) * | 2018-12-27 | 2020-07-02 | 成都海创药业有限公司 | 一种fak抑制剂及其联合用药物 |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| EP3928792A4 (en) | 2019-02-20 | 2022-12-14 | Saitama Medical University | BIOMARKERS IN PERIPHERAL BLOOD FOR ASSESSING THE ANTI-TUMORS IMMUNE EFFECT OF RADIATION THERAPY |
| MA55088A (fr) * | 2019-02-28 | 2022-01-05 | Taiho Pharmaceutical Co Ltd | Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire |
| WO2020202005A1 (en) * | 2019-04-02 | 2020-10-08 | Inxmed (Shanghai) Co., Ltd. | Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors |
| TWI757716B (zh) * | 2019-04-15 | 2022-03-11 | 禾榮科技股份有限公司 | 微創型中子束產生裝置及微創型中子捕獲治療系統 |
| JP7199523B2 (ja) | 2019-05-10 | 2023-01-05 | 富士フイルム株式会社 | 光照射装置およびセンサー |
| CN110201171A (zh) * | 2019-06-18 | 2019-09-06 | 北京大学 | Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用 |
| CN114641310A (zh) * | 2019-06-21 | 2022-06-17 | 德克萨斯大学系统董事会 | 治疗癌症和其他疾病的靶向α3β1整合素 |
| AU2020310853A1 (en) * | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| AU2020388848A1 (en) * | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
| MY209389A (en) * | 2019-11-28 | 2025-07-07 | Inxmed Nanjing Co Ltd | Use of bi853520 in cancer treatment |
| CN115279376A (zh) * | 2020-01-31 | 2022-11-01 | 维瑞斯特姆股份有限公司 | 用于治疗异常细胞生长的组合疗法 |
| MX2022009612A (es) | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
| JP7470775B2 (ja) | 2020-02-14 | 2024-04-18 | 富士フイルム株式会社 | 光結合システムおよび光通信デバイス |
| AU2021307410A1 (en) * | 2020-07-13 | 2023-02-09 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| TW202206425A (zh) * | 2020-08-03 | 2022-02-16 | 大陸商應世生物科技（南京）有限公司 | 化合物的固體形式 |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2022125652A1 (en) * | 2020-12-08 | 2022-06-16 | Cornell University | Methods of inducing an immunomodulatory tumor response |
| EP4259123A4 (en) * | 2020-12-11 | 2024-11-20 | Materia Therapeutics Inc. | TREATMENT OF CANCER USING BOSENTAN IN COMBINATION WITH A CHECKPOINT INHIBITOR |
| TW202313044A (zh) | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| JP2024545147A (ja) * | 2021-12-10 | 2024-12-05 | ▲應▼世生物科技（南京）有限公司 | 腫瘍治療の医薬組合せ及び使用 |
| CN116889565A (zh) * | 2022-04-07 | 2023-10-17 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| KR20250052367A (ko) * | 2022-08-24 | 2025-04-18 | 인엑스메드 (난징) 컴퍼니 리미티드 | Fak 억제제와 미세소관 억제제의 약제학적 병용물 및 이의 용도 |
| CN119816326A (zh) * | 2022-09-05 | 2025-04-11 | 应世生物科技(南京)有限公司 | Fak抑制剂及egfr-tki的药物组合及用途 |
| TW202412766A (zh) * | 2022-09-16 | 2024-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｆａｋ抑制劑及拓撲異構酶抑制劑的藥物組合及用途 |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| AU2024211503A1 (en) * | 2023-01-24 | 2025-07-31 | Msd International Business Gmbh | Methods and compositions for combination therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US20030009158A1 (en) | 2001-07-09 | 2003-01-09 | Perricone Nicholas V. | Skin treatments using blue and violet light |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| FI20030976A7 (fi) | 2003-06-30 | 2004-12-31 | M Real Oyj | Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi |
| ATE534301T1 (de) | 2004-06-30 | 2011-12-15 | Cadbury Holdings Ltd | Kaugummi mit aromastoffemulsion |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| US20140155410A1 (en) | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| RU2014102595A (ru) * | 2011-06-28 | 2015-08-20 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Способ введения и лечения |
| EP2903644A4 (en) * | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
| WO2015061796A1 (en) | 2013-10-25 | 2015-04-30 | Nodality Inc. | Methods and compositions for immunomodulation |
| JP2016535989A (ja) * | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
| ES2779975T3 (es) * | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| WO2017201043A1 (en) | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
-
2016
- 2016-06-29 JP JP2017568200A patent/JP2018519327A/ja not_active Withdrawn
- 2016-06-29 CN CN202111345764.0A patent/CN114209841A/zh active Pending
- 2016-06-29 CA CA3244408A patent/CA3244408A1/en active Pending
- 2016-06-29 IL IL256652A patent/IL256652B2/en unknown
- 2016-06-29 US US15/738,999 patent/US10532056B2/en active Active
- 2016-06-29 EA EA201890161A patent/EA201890161A1/ru unknown
- 2016-06-29 IL IL322086A patent/IL322086A/en unknown
- 2016-06-29 CN CN201680044292.6A patent/CN108289892B/zh active Active
- 2016-06-29 EP EP16818676.5A patent/EP3313404B1/en active Active
- 2016-06-29 AU AU2016286091A patent/AU2016286091B2/en active Active
- 2016-06-29 MX MX2018000288A patent/MX389683B/es unknown
- 2016-06-29 KR KR1020187002706A patent/KR102783581B1/ko active Active
- 2016-06-29 EP EP24197649.7A patent/EP4488265A3/en active Pending
- 2016-06-29 ES ES16818676T patent/ES2987376T3/es active Active
- 2016-06-29 CA CA2991044A patent/CA2991044C/en active Active
- 2016-06-29 WO PCT/US2016/040080 patent/WO2017004192A1/en not_active Ceased
-
2018
- 2018-01-08 MX MX2022001165A patent/MX2022001165A/es unknown
- 2018-01-26 ZA ZA2018/00572A patent/ZA201800572B/en unknown
-
2019
- 2019-11-25 US US16/694,384 patent/US11564927B2/en active Active
-
2021
- 2021-04-19 AU AU2021202379A patent/AU2021202379B2/en active Active
- 2021-09-03 JP JP2021143803A patent/JP2021183650A/ja not_active Withdrawn
-
2022
- 2022-12-21 US US18/085,792 patent/US20240000790A1/en active Pending
-
2023
- 2023-08-09 AU AU2023214272A patent/AU2023214272B2/en not_active Expired - Fee Related
-
2024
- 2024-06-21 JP JP2024100476A patent/JP2024111247A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519327A5 (https=) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| Kim et al. | A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer | |
| JP2018508512A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| JP2020532537A5 (https=) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2016516800A5 (https=) | ||
| Froesch et al. | Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial | |
| Jiang et al. | Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. | |
| JPWO2022270524A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| HK1225995A1 (zh) | 用於治疗或缓解高龄或晚期癌症患者的药物组合物 | |
| Bironzo et al. | Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? | |
| Benitez et al. | Hepatic intra-arterial chemotherapy with immunotherapy in NSCLC | |
| TW202317183A (zh) | 藉由併用ｃｄ４７抑制物質、免疫檢查點抑制物質及標準療法之癌症治療法 | |
| NZ739490B2 (en) | Therapeutic compositions, combinations, and methods of use | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| Alquraini | Dostarlimab: Novel paradigm shift in cancer therapy. | |
| JPWO2022270523A5 (https=) | ||
| EP4637731A1 (en) | Combination therapy for treating cancer | |
| CN117460534A (zh) | 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法 | |
| HK40125832A (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | |
| NZ739490A (en) | Therapeutic compositions, combinations, and methods of use | |
| Lakhani et al. | A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non-Hodgkin Lymphoma |